Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
421.95(c) 426.9(c) 421.4(c) 412.8(c) 411.4(c) Last
2 568 187 2 328 246 2 459 116 2 955 109 2 588 876 Volume
+0.42% +1.17% -1.29% -2.04% -0.34% Change
More quotes
Financials
Sales 2020 127 B 20 412 M 20 412 M
Net income 2020 42 174 M 6 757 M 6 757 M
Net cash position 2020 8 472 M 1 357 M 1 357 M
P/E ratio 2020 22,7x
Yield 2020 2,19%
Sales 2021 135 B 21 636 M 21 636 M
Net income 2021 45 207 M 7 242 M 7 242 M
Net cash position 2021 12 773 M 2 046 M 2 046 M
P/E ratio 2021 20,8x
Yield 2021 2,36%
Capitalization 952 B 152 B 153 B
EV / Sales 2020 7,41x
EV / Sales 2021 6,96x
Nbr of Employees 44 326
Free-Float 75,1%
More Financials
Company
Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84.3%); - hemophilia treatment products (8.4%): mainly injections of protein; - growth hormones (6%): used for treatment of growth deficiencies in children; - hormone replacement products (1.3%): used for treatment of... 
Sector
Pharmaceuticals
Calendar
02/03Earnings Release
More about the company
Notations Surperformance© of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
All news about NOVO NORDISK A/S
11/23NOVO NORDISK A/S : – Share repurchase programme
AQ
11/20India's Gland Pharma jumps 23% in market debut
RE
11/18NOVO NORDISK A/S : - Once-weekly semaglutide 2.0 mg demonstrates superior reduct..
AQ
11/18NOVO NORDISK A/S : Experts Urge Govt to Subsidise Cost of Diabetes Management, T..
AQ
11/17NOVO NORDISK A/S : Once-weekly semaglutide 2.0 mg demonstrates superior reductio..
AQ
11/16GILEAD SCIENCES : and Novo Nordisk Present New Data from Proof-of-Concept Trial ..
AQ
11/14NOVO NORDISK A/S : Diabetes - Novo Nordisk to Offer Free Insulin to Children in ..
AQ
11/12NOVO NORDISK A/S : set to acquire Emisphere for $1.8 billion
AQ
11/09NOVO NORDISK A/S : to acquire Emisphere Technologies and obtain ownership of the..
AQ
11/09NOVO NORDISK : UBS reiterates its Neutral rating
MD
11/09NOVO NORDISK : Downgraded to Sell by Morgan Stanley
MD
11/09NOVO NORDISK A/S : – Share repurchase programme
AQ
11/06Macron pitches France Inc as post-COVID-19 investment destination
RE
11/06NOVO NORDISK : JP Morgan maintains a Buy rating
MD
11/06NOVO NORDISK : Goldman Sachs maintains a Buy rating
MD
More news
News in other languages on NOVO NORDISK A/S
11/19Ypsomed confie à Eli Lilly la distribution future de l'Ypsopump aux Etats-Uni..
11/13Givaudan s'associe au danois Novozymes pour la recherche
11/12JPMorgan senkt Novo-Nordisk-Ziel auf 470 Kronen - 'Overweight'
11/09Aktien Europa Schluss: Wahlsieg Bidens und Impfstoff-Hoffnung treiben an
11/09NOVO NORDISK : UBS est neutre sur le titre
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 439,69 DKK
Last Close Price 411,40 DKK
Spread / Highest target 32,5%
Spread / Average Target 6,88%
Spread / Lowest Target -29,5%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S6.40%152 415
JOHNSON & JOHNSON-1.50%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-1.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273